

Special Issue

Antimicrobial Resistance and Epidemiological Study of Clinically Relevant Pathogens, 2nd Edition

Message from the Guest Editors

The escalating threat of bacterial resistance poses a significant challenge in contemporary healthcare, leading to critical clinical implications that profoundly impact treatment options. In recent years, infections caused by multidrug-resistant organisms (MDROs) have become endemic in numerous healthcare facilities, resulting in hospital-acquired outbreaks reported globally. In this context, we invite contributions for our Special Issue, with a focus on, but not limited to, the following topics:

- The molecular characterization of multidrug-resistant bacteria;
- Correlation between antibiotic use and resistance patterns;
- The identification of risk factors for acquired multidrug resistance;
- The evaluation of local trends in multidrug-resistant bacteria;
- The investigation of novel methods for rapid resistance detection;
- The assessment of antimicrobial activity of new compounds;
- The relationship between the environment and resistant pathogens.

We encourage submissions of both original research and review articles.

Guest Editors

Dr. Florin George Horhat

Dr. Adrian Man

Dr. Delia Muntean

Deadline for manuscript submissions

30 September 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/267330

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)